Lineage Cell Therapeutics (LCTX) Treasury Shares (2011 - 2016)

Lineage Cell Therapeutics' Treasury Shares history runs 6 years deep, the most recent figure standing at $2.9 million for Q4 2016.

• In Q4 2016, Treasury Shares fell 83.97% year-over-year to $2.9 million; the TTM figure through Dec 2016 stood at $2.9 million (down 83.97% YoY), while the FY2016 annual figure was $2.9 million, down 83.97% from the prior year.
• Treasury Shares for Q4 2016 stood at $2.9 million, roughly flat from $2.9 million in the prior quarter.
• The five-year high for Treasury Shares was $939000.0 in Q4 2022, with the low at $248000.0 in Q1 2026.
• The 5-year median for Treasury Shares is $501000.0 (2024), against an average of $494583.3.
• The sharpest annual moves came in 2013 and 2016: Treasury Shares soared 413.81% in 2013, then tumbled 85.47% in 2016.
• Lineage Cell Therapeutics' Treasury Shares stood at $8.4 million in 2012, then jumped by 413.81% to $43.0 million in 2013, then plunged by 53.78% to $19.9 million in 2014, then dropped by 9.34% to $18.0 million in 2015, then plunged by 83.97% to $2.9 million in 2016.
• Business Quant data shows LCTX's Treasury Shares at $2.9 million in Q4 2016, $2.9 million in Q3 2016, and $2.9 million in Q2 2016.